BLFS Stock Overview
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally.
BioLife Solutions, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$23.67|
|52 Week High||US$58.80|
|52 Week Low||US$10.40|
|1 Month Change||0.77%|
|3 Month Change||61.68%|
|1 Year Change||-44.07%|
|3 Year Change||46.38%|
|5 Year Change||310.94%|
|Change since IPO||-95.64%|
Recent News & Updates
BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
|BLFS||US Medical Equipment||US Market|
Return vs Industry: BLFS underperformed the US Medical Equipment industry which returned -30.1% over the past year.
Return vs Market: BLFS underperformed the US Market which returned -20.3% over the past year.
|BLFS Average Weekly Movement||11.7%|
|Medical Equipment Industry Average Movement||8.6%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: BLFS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: BLFS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials.
BioLife Solutions, Inc. Fundamentals Summary
|BLFS fundamental statistics|
Is BLFS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BLFS income statement (TTM)|
|Cost of Revenue||US$105.54m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.20|
|Net Profit Margin||-63.44%|
How did BLFS perform over the long term?See historical performance and comparison